Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction regorafenib plus metronomic chemotherapy and low-dose aspirin before second-line chemotherapy in metastatic colorectal cancer
2022-003577-34Phase 2Active
- Sponsor
- CHU de Besançon
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of regorafenib in metastatic colon cancer (mCRC) (2 arms), sponsored by CHU de Besançon. Primary endpoint: Overall survival. Started Nov 2022; status: active.
02
Drugs
regorafenib
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on 2022-003577-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003577-34.